One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study
EuroInterv.2007;3:315-320.
Peter N. Ruygrok1*, MD, FRACP; Martin Desaga2, MD; Franck Van Den Branden3, MD; Klaus Rasmussen4, MD; Harry Suryapranata5, MD; Cécile Dorange6, MSc; Susan Veldhof6, RN; Patrick W. Serruys7, MD, PhD; on behalf of the SPIRIT II Investigators
1. Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; 2. Amper kliniken AG, Klinikum Dachau, Dachau, Germany; 3. A.Z. Middelheim, Antwerpen, Belgium; 4. Aalborg Sygehus Syd, Aalborg, Denmark; 5. Isala Klinieken, Zwolle, The
Aims: The SPIRIT II study randomised 300 patients in a ratio of 3:1 to receive either a XIENCE V or a TAXUS stent. The six month clinical and angiographic results have previously been repor